SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Two San Diego life science companies reported earnings Tuesday afternoon, one missing Wall Street expectations and the other beating predictions.
DJO Global Inc., a medical device company based in Vista, announced its first quarter results, ending April 1.
Ending a months-long search for a new chief executive, San Diego’s Arena Pharmaceuticals Inc. announced Tuesday that it has appointed Amit D. Munshi as president, CEO, and interim principal financial officer.
San Diego drugmaker Otonomy Inc. reported financial earnings and a corporate update Monday.
San Diego-based biopharmaceutical company Apricus Biosciences Inc. reported total revenue of $626,000 for the first quarter of 2016, with a net loss of $2.5 million.
Shares of Sophiris Bio Inc. are down over 18 percent Monday after the La Jolla firm announced plans to sell shares in the company at $1.40 per share to raise about $5 million.
San Diego’s biopharmaceutical firm Sorrento Therapeutics Inc. has hired advisors to help the company come up with strategies to boost shareholder value, the company said in a news release. The announcement comes shortly after a minority shareholder publicly expressed dissatisfaction with the company’s management.
Biosortia Pharmaceuticals Inc., a biopharma company that recently moved to San Diego from Ohio, has launched three new oncology research projects.
Two San Diego drugmakers reported financial earnings Thursday.
A nonprofit community clinic has more than doubled its footprint in Linda Vista following a surge of newly-insured patients. Linda Vista Health Center, part of a seven-clinic umbrella corporation called San Diego Family Care, has added 23,000 square feet to its existing space in a $2.7 million expansion to accommodate the need.
PHARMA: Acadia Prepares To Launch Drug to Treat Parkinson’s Psychosis
Acadia Pharmaceuticals Inc. has earned the greenlight from regulators to sell a valuable antipsychotic drug. The medication, potentially worth billions, quells the hallucinations and delusions experienced by Parkinson’s disease patients. And it’s the first of its kind.
Three public life science firms in San Diego are suffering stock slips after reporting first quarter earnings Wednesday. Two of the firms missed analyst expectations and one exceeded Wall Street’s forecast, but barely.
In a deal worth up to $95 million-plus, San Diego drugmaker Ionis Pharmaceuticals sold global rights to develop and commercialize its marketed drug Kynamro to Chicago-based Kastle Therapeutics.
San Diego’s Illumina Inc. reported quarterly earnings May 3, falling short of analyst expectations and further slipping the company’s stock.
Dexcom Inc., one of San Diego’s biggest public medical technology firms, announced May 2 that it will acquire Nintamed, a distribution partner with presence in Germany, Switzerland and Austria.